Optical coherence tomography creates detailed cross-sectional images of the retina, optic nerve head and other eye structures. It can measure retinal-layer thickness and identify changes that may not be visible during a standard eye examination. OCT has established roles in diagnosing and monitoring several eye conditions and can support selected neuro-ophthalmic assessments. Researchers are also investigating associations with wider neurological and systemic diseases, but an OCT scan cannot independently diagnose most of these conditions. Why Can Your Retina Reflect General

The retina contains nerve tissue and a visible network of small blood vessels that can be examined without surgery. Changes at the back of the eye may sometimes provide clues about conditions affecting your circulation, nervous system or other organs. A retinal examination cannot provide a complete assessment of your general health or diagnose most systemic diseases. Unexpected findings may instead prompt your eye specialist to recommend medical assessment or further tests. Why Is the Retina Linked to General Health?

Biological changes associated with Alzheimer’s disease may begin years before noticeable memory or thinking difficulties develop. Researchers are investigating whether structural, vascular or biochemical changes in the retina could provide additional clues about these early processes. Studies using OCT, OCT angiography, retinal photography and experimental light-based imaging have reported promising differences between research groups. However, retinal imaging cannot currently diagnose, predict or exclude Alzheimer’s disease and should not replace assessment by a memory specialist. Why Are Researchers Studying the Eyes?

Diabetic retinopathy can develop before you notice changes in your vision. Researchers are investigating whether proteins, inflammatory molecules and genetic material in tears could provide additional information about diabetes-related eye changes. Tear biomarkers are not currently used to diagnose or screen for diabetic retinopathy in routine care. Research remains exploratory, and retinal photography, specialist examination and other established imaging tests are still required. Why Are Researchers Studying Tear Biomarkers? Diabetic retinopathy can begin developing before you notice any changes in

If you have persistent dryness, irritation, watering or fluctuating vision, an eye examination may identify dry eye disease or another ocular-surface condition. However, symptoms alone do not always reveal whether inflammation, allergy, tear-film instability, eyelid problems or another factor is contributing. At Eye Clinic London, point-of-care tear biomarker testing may be used to measure selected markers such as MMP-9, total tear IgE and lymphotoxin-alpha. A tiny tear sample is analysed during the consultation, but the result is interpreted alongside your

Your tears contain proteins, lipids, electrolytes and other biological molecules that can provide information about the ocular surface. Selected tear-based measurements are already used in some dry-eye assessments, while researchers are investigating much broader biomarker panels for conditions affecting the cornea, retina and optic nerve. Most advanced applications remain in the research or validation stage and should not replace a comprehensive eye examination, imaging or established screening. In the future, validated tear tests may add molecular information to your symptoms

Tear biomarker testing can help identify certain biological changes in your eyes, such as inflammation or changes in tear composition. However, the accuracy of the result depends on the specific biomarker being measured, the condition being assessed and how the tear sample is collected and analysed. A tear biomarker result should not usually be considered a diagnosis on its own. Your clinician will interpret the findings alongside your symptoms, medical history and eye examination to understand what the results mean

Tears contain proteins, lipids, enzymes, antibodies and inflammatory molecules that can change when the tear film or ocular surface is affected by disease. These substances are known as tear biomarkers and may provide additional information about inflammation, tear stability and surface damage. Tear osmolarity and MMP-9 testing may support the assessment of dry eye disease in some clinics. Most other tear biomarkers remain research tools and cannot currently diagnose a specific eye condition without your symptoms, medical history and a

Dry eye treatment does not always follow a straightforward path. You may try lubricating eye drops, eyelid care, prescription treatments, or lifestyle changes and find that some options provide only limited relief. This is because dry eye disease can develop from different underlying causes. Your symptoms may be linked to rapid tear evaporation, reduced tear production, inflammation, meibomian gland dysfunction, damage to the eye surface, changes in corneal nerve function, or a combination of these factors. Tear biomarkers may help

Dry eye disease may seem straightforward when your eyes feel gritty, sore, watery or tired, or when your vision occasionally becomes blurred. However, these symptoms can be caused by several different problems involving your tears, eyelids, oil glands, corneal nerves, or the surface of the eye. This is one reason why dry eye disease can be difficult to diagnose based on symptoms alone. You may have symptoms that are very similar to someone else's, yet the underlying cause can be